NEW YORK (GenomeWeb) – Molecular diagnostics firm Great Basin Scientific announced today that the US Food and Drug Administration has granted 510(k) clearance for its Group B Streptococcus test.

The company plans a commercial launch of the GBS assay in the second quarter of 2015.

"Receiving FDA clearance for our GBS test represents a significant milestone for Great Basin, both as an expansion of our menu and as evidence of the company's ability to meet product deliverables," Great Basin CEO and Co-founder and CEO Ryan Ashton said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.